在专业心力衰竭指南指导的医疗疗优化计划中的耐受性和不良影响
Claudia Mae Velasco1, Gladys Baksh2, Michele Haydo2
1Penn State College of Medicine, Hershey, Pennsylvania, USA.
Clinical cardiology
|July 15, 2025
概括
优化心力衰竭 (HF) 药物剂量是具有挑战性的,因为不良反应 (AE). 一个专门的HF计划发现,超过一半的患者经历了阻碍最佳治疗定位的副作用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 针对心力衰竭 (HF) 的指南导向医疗疗 (GDMT) 在目标剂量时通常未得到充分利用.
- 副作用 (AE),生理因素和治疗惯性有助于低于最佳GDMT.
- 这项研究在一个专门的高频优化程序中研究了耐受性和定位限制的AE.
研究的目的:
- 探索GDMT在HF患者中的耐受性.
- 为了确定常见的副作用,限制GDMT定位到目标剂量.
- 分析与低于最佳的GDMT剂量相关的患者特征.
主要方法:
- 对254名完成专门的高频优化计划的患者进行了回顾性分析.
- 评估患者达到目标GDMT剂量的基线特征.
- 分析了四种常见的与GDMT相关的副作用的频率和严重程度:低血压,胸,高胆血症和功能障碍.
主要成果:
- 达到目标剂量的患者更年轻,更有可能患有非胰岛素HF,并且不太可能患有最近的HF住院或冠状动脉疾病.
- 低于最佳的β-阻断剂剂量与老年,心房动和没有高血压有关.
- 低于最佳的ACEI/ARB/ARNI剂量与心房动有关.
- 59.1%的患者经历了至少一个阻碍GDMT定位的AE.
结论:
- 在专门的高频程序中,GDMT优化是复杂的.
- 需要对与GDMT相关的AE进行标准化定义.
- 对AE的有效管理策略对于改善GDMT定位至关重要.
相关概念视频
01:30Heart Failure V: Medical Management
27
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
27
01:22Heart Failure VI: Adjunct Therapies
31
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
31
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
513
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
513
01:22Heart Failure Drugs: β-Blockers
435
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
435
01:26Heart Failure Drugs: Inotropic Agents
733
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
733
01:22Heart Failure Drugs: Diuretics
496
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
496